Compare Okta, Inc. (OKTA) vs BIO-TECHNE Corp (TECH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Okta, Inc. vs BIO-TECHNE Corp — how do they compare? Okta, Inc. trades at $221.54 (market cap $38.11B), while BIO-TECHNE Corp trades at $72.46 (market cap $11.37B). The key difference: Okta, Inc. is far larger — about 3.4× BIO-TECHNE Corp's market cap, and BIO-TECHNE Corp pays a 0.44% dividend while Okta, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold Okta, Inc. for 44 Days and BIO-TECHNE Corp for 63 Days on average.
| OKTA | TECH | |
|---|---|---|
Market Cap | $38.11B | $11.37B |
Volume | 2,259,293 | 3,153,511 |
Sector | Technology | Health |
52-Week High | $220.21 | $72.61 |
52-Week Low | $62.93 | $43.31 |
Typical Hold Time | 44 Days | 63 Days |
Enterprise Value | $35.86B | $11.40B |
Dividend Yield | — | 0.44% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
OKTA trades at $220.21, up 0.7% with strong technical momentum and bullish moving averages. The company shows improving fundamentals with revenue growth from $2.3B to $2.6B and a return to profitability in 2025. Recent earnings beats and positive analyst sentiment (73.6% buy ratings) support the bullish case, though high valuation multiples and insider selling present cautionary notes.
Outlook remains positive with AI security initiatives driving growth potential, but investors face valuation risks at current levels. The stock trades above consensus price target, suggesting limited near-term upside despite strong operational improvements and market positioning in the cybersecurity sector.
TECH trades at $72.53, near its 52-week high of $72.70, with a bullish technical signal and strong institutional interest. Recent earnings show mixed results, beating in Q2 2026 but missing in Q1. The company maintains solid profitability with a 65.77% gross margin, though net income declined to $73.40M in 2025. Shareholders approved an acquisition by Merck KGaA at $73.00 per share, a key near-term catalyst.
Outlook is positive due to the pending acquisition, but risks include execution challenges and valuation concerns with a high P/E of 62.53. Analyst consensus is divided with 46% buy ratings, suggesting cautious optimism. The stock offers limited upside to the acquisition price, making it suitable for event-driven investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Okta, Inc.
Okta is a cloud-native security company that focuses on identity and access management. The San Francisco-based firm went public in 2017 and focuses on two key client stakeholder groups: workforces and customers. Okta's workforce offerings enable a company's employees to securely access its cloud-based and on-premises resources. The firm's customer offerings allow its clients' customers to securely access the client's applications.
Read more on OKTA →About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →
